Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram
Recurrence/progression-free survival and overall survival among... | Download Scientific Diagram
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Cancers | Free Full-Text | Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials - ScienceDirect
Extrapolation from Progression Free Survival to Overall Survival in Oncology | PPT
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Extrapolation from Progression-Free Survival to Overall Survival in Oncology - OHE
Survival analysis in hematologic malignancies: recommendations for clinicians | Haematologica
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
Progression-free survival (PFS) curve and overall survival (OS) curve... | Download Scientific Diagram
Progression-free survival and overall survival probabilities. | Download Scientific Diagram
Progression free survival and overall survival in patients treated with... | Download Scientific Diagram
Estimating progression-free survival in patients with glioblastoma using routinely collected data | Journal of Neuro-Oncology
The Arts, Sciences and Medicine: Progression Free Survival (PFS)
Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Comparison of progression-free survival (A) or overall survival (B)... | Download Scientific Diagram
Correlation between progression-free survival and overall survival in patients with ovarian cancer after cytoreductive surgery: a systematic literature review | International Journal of Gynecologic Cancer
